Investigation of the Mechanism of Shengmai Injection on Sepsis by Network Pharmacology Approaches

Table 5

Key targets and topological parameters of the network on SMI in the treatment of sepsis.

No.	Gene name	Protein name	Degree	Closeness centrality	Betweenness centrality
1	ABL1	Tyrosine-protein kinase ABL1	43	0.548	0.101
2	CCND1	G1/S-specific cyclin-D1	42	0.522	0.046
3	RB1	Retinoblastoma-associated protein	41	0.509	0.037
4	CDK2	Cyclin-dependent kinase 2	41	0.52	0.026
5	HSP90AA1	Heat-shock protein HSP 90-alpha	40	0.531	0.077
6	CDK1	Cyclin-dependent kinase 1	39	0.509	0.023
7	CDK6	Cyclin-dependent kinase 6	39	0.502	0.015
8	SMARCA4	Transcription activator BRG1	37	0.511	0.037
9	CDKN1B	Cyclin-dependent kinase inhibitor 1B	37	0.506	0.031
10	RBL2	Retinoblastoma-like protein 2	36	0.482	0.04
11	CTNNB1	Catenin beta-1	36	0.509	0.036
12	MDM2	E3 ubiquitin-protein ligase Mdm2	35	0.488	0.025
13	SP1	Transcription factor Sp1	34	0.504	0.027
14	LRRK1	Leucine-rich repeat serine/threonine-protein kinase 1	31	0.515	0.115
15	BTK	Tyrosine-protein kinase BTK	23	0.486	0.038
16	PIK3R1	Phosphatidylinositol 3-kinase regulatory subunit alpha	21	0.47	0.054
17	TMPRSS11D	Transmembrane protease serine 11D	20	0.463	0.041
18	ACTG2	Actin, gamma-enteric smooth muscle	20	0.454	0.025
19	CD79A	B-cell antigen receptor complex-associated protein alpha chain	19	0.458	0.058
20	RET	Proto-oncogene tyrosine-protein kinase receptor Ret	19	0.463	0.032